Serial Number | 90596751 |
Word Mark | CRISPR BY DESIGN |
Filing Date | Tuesday, March 23, 2021 |
Status | 734 - FIFTH EXTENSION - GRANTED |
Status Date | Tuesday, January 28, 2025 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, June 21, 2022 |
Goods and Services | Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeuticsin the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders |
Goods and Services | Molecular diagnostic testing, monitoring and reporting services for medical purposes and medical research purposes; Medical diagnostic testing services in the field of human disease and human medical conditions |
NOT AVAILABLE | "CRISPR" |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Monday, June 28, 2021 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Monday, June 28, 2021 |
Primary Code | 044 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Scribe Therapeutics Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Alameda, CA 94501 |
Party Name | Scribe Therapeutics Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Alameda, CA 94501 |
Event Date | Event Description |
Friday, March 26, 2021 | NEW APPLICATION ENTERED |
Monday, June 28, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Wednesday, October 27, 2021 | ASSIGNED TO EXAMINER |
Thursday, October 28, 2021 | NON-FINAL ACTION WRITTEN |
Thursday, October 28, 2021 | NON-FINAL ACTION E-MAILED |
Thursday, October 28, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, April 26, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Tuesday, April 26, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Wednesday, June 1, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, June 21, 2022 | PUBLISHED FOR OPPOSITION |
Tuesday, June 21, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, August 16, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Wednesday, February 8, 2023 | SOU TEAS EXTENSION RECEIVED |
Wednesday, February 8, 2023 | SOU EXTENSION 1 FILED |
Wednesday, February 8, 2023 | SOU EXTENSION 1 GRANTED |
Thursday, August 10, 2023 | SOU TEAS EXTENSION RECEIVED |
Thursday, August 10, 2023 | SOU EXTENSION 2 FILED |
Thursday, August 10, 2023 | SOU EXTENSION 2 GRANTED |
Saturday, August 12, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Thursday, February 8, 2024 | SOU EXTENSION 3 FILED |
Thursday, February 8, 2024 | SOU EXTENSION 3 GRANTED |
Thursday, February 8, 2024 | SOU TEAS EXTENSION RECEIVED |
Tuesday, April 26, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Thursday, May 19, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Friday, February 10, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, February 9, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Wednesday, August 14, 2024 | SOU EXTENSION 4 FILED |
Wednesday, August 14, 2024 | SOU TEAS EXTENSION RECEIVED |
Monday, August 19, 2024 | DIVISIONAL REQUEST RECEIVED |
Monday, August 19, 2024 | TEAS REQUEST TO DIVIDE RECEIVED |
Wednesday, October 23, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Monday, November 18, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Friday, November 22, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Monday, December 16, 2024 | DIVISIONAL PROCESSING COMPLETE |
Monday, December 16, 2024 | SOU EXTENSION 4 GRANTED |
Monday, December 16, 2024 | CORRECTED NOA E-MAILED |
Wednesday, January 22, 2025 | SOU EXTENSION 5 FILED |
Wednesday, January 22, 2025 | SOU TEAS EXTENSION RECEIVED |
Tuesday, January 28, 2025 | SOU EXTENSION 5 GRANTED |
Wednesday, January 29, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Monday, December 16, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |